Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Qingqing Cai, Yi Xia, Huiqiang Huang, Ying Zhao, Fan Yang, Wenning Xu, Hongyan Tong, Chunmei Yang, Xiaojie Fang, Man Nie, Yu Fang, Gao Yan, Xuanye Zhang, Rong Tao, Xiuhua Sun, Xueyi Pan, Tao Wu, Yuchen Zhang, Jun Cai

Blood (2024) 144 (Supplement 1): 6407.

https://doi.org/10.1182/blood-2024-206564

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Blood (2024) 144 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2024-209224

Published: 2024

Journal Articles

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Zheng Song, Ying Cheng, Haiyan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Yiqian Fang, Jiaoyan Lyu, Keshu Zhou, Huilai Zhang

Blood (2024) 144 (Supplement 1): 986.

https://doi.org/10.1182/blood-2024-193167

Published: 2024

Journal Articles

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Gao Yan, Xue-Ping Li, Bing Bai, Xiaoxiao Wang, Xuanye Zhang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2024-205253

Published: 2024

Journal Articles

Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch

Rong Tao, Chuanxu Liu, Yan Gao, Yang Yu, Zhi Guo, Jun Zhao, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2024-206554

Published: 2024

Journal Articles

Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Phase I Study

Suying Lu, Junting Huang, Ruiqing Cai, Yan Gao, Jia Zhu, Juan Wang, Yi Que, Zi-Jun Zhen, Feifei Sun, Huiqiang Huang, Yizhuo Zhang

Blood (2024) 144 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2024-209718

Published: 2024

Journal Articles

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Gao Yan, Xue-Ping Li, Xiaoxiao Wang, Xiaoyu Hong, Bing Bai, Xuanye Zhang, Jialing Zhuang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2024-207630

Published: 2024

Journal Articles

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

Gao Yan, Qingqing Cai, Zhiming Li, Xiaoxiao Wang, Yi Xia, Xuanye Zhang, He Huang, Bin Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6147.

https://doi.org/10.1182/blood-2023-181619

Published: 2023

Journal Articles

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

Yanxia He, Yan Gao, Xiaoxiao Wang, Bing Bai, Zhiming Li, Haixia He, Liqin Ping, Cheng Huang, Haoqing Chen, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6218.

https://doi.org/10.1182/blood-2023-186496

Published: 2023

Journal Articles

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2 ) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Lorenzo Falchi, Franck Morschhauser, Kim Linton, Huiqiang Huang, Faith Galderisi, Syed Quadri, Lingmin Zeng, Daniela Hoehn, John F. Seymour

Blood (2023) 142 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2023-180092

Published: 2023

Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2023-186252

Published: 2023

Journal Articles

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

Liqin Ping, Xiaoxiao Wang, Yan Gao, Bing Bai, He Huang, Linbo Cai, Hui Zhou, Changguo Shan, Zhiming Li, Mingyao Lai, Haixia He, Cheng Huang, Haoqing Chen, Ru Feng, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2023-185212

Published: 2023

Journal Articles

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yu-Hua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2023-186099

Published: 2023

Journal Articles

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Yuqin Song, Shuhua Yi, Haiyan Yang, Ru Feng, Huiqiang Huang, Qingyuan Zhang, Yanyan Liu, Ye Guo, Huilai Zhang, Liling Zhang, Yijiao Qian, JianKun Zhu, Jun Zhu

Blood (2023) 142 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2023-173287

Published: 2023

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial

Qingqing Cai, Yi Xia, Liang Wang, Huiqiang Huang, Jinni Wang, Jun Cai, Xiaopeng Tian

Blood (2023) 142 (Supplement 1): 4470.

https://doi.org/10.1182/blood-2023-188430

Published: 2023

Journal Articles

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R 2 ) Vs R 2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Lorenzo Falchi, Franck Morschhauser, John G. Gribben, Huiqiang Huang, Minh Dinh, Rebekah Conlon, Xiaorong Chen, Brian Elliot, John F. Seymour

Blood (2022) 140 (Supplement 1): 9338–9339.

https://doi.org/10.1182/blood-2022-157584

Published: 2022

Journal Articles

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Huiqiang Huang, Yan Gao, Huilai Zhang, Keshu Zhou, Jianqiu Wu, Zhen Cai, Hongmei Jing, LEI Fan, Sai Lou, Yizhou Fei, Aihua Wang, Kevin Lynch

Blood (2022) 140 (Supplement 1): 6554–6555.

https://doi.org/10.1182/blood-2022-165797

Published: 2022

Journal Articles

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

Qingqing Cai, Yi Xia, Panpan Liu, Yuchen Zhang, Huiqiang Huang, Yan Gao, Guowei Li, Xiuhua Sun, Xueyi Pan

Blood (2022) 140 (Supplement 1): 9356–9357.

https://doi.org/10.1182/blood-2022-166237

Published: 2022

Journal Articles

A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Xiaoxiao Wang, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Yan Gao, Shanshan Yu, Xiaoyu Hong, Mingyao Lai, Chao Yang, Yang Shao, Linbo Cai, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 6606–6607.

https://doi.org/10.1182/blood-2022-169608

Published: 2022

Journal Articles

Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Huilai Zhang, Keshu Zhou, Ying Cheng, Liling Zhang, Haiyan Yang, Liqun Zou, Junning Cao, Huiqiang Huang, Ye Guo, Zhao Wang, Sha Huang, Zhiyu Liang, Hui Yao, Haiyi Guo, Yiqian Fang, Hongjie Zhu

Blood (2022) 140 (Supplement 1): 3750–3752.

https://doi.org/10.1182/blood-2022-155979

Published: 2022

NARROW

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch

Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Phase I Study

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2 ) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R 2 ) Vs R 2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only